AcelRx Pharmaceuticals Announces Zalviso™ and ARX-04 Data Presentations at the American Pain Society 33rd Annual Scientific Meeting

May 1, 2014

REDWOOD CITY, Calif., May 1, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that multiple Zalviso and ARX-04 data presentations will be made at the American Pain Society's (APS) 33rd Annual Scientific Meeting held on April 30 to May 3 in Tampa, Florida. The APS Annual Scientific Meeting is the premier pain meeting in the United States with more than 1,000 scientists and clinicians specializing in pain and pain management expected to attend.

The details of the presentations are as follows:

Title: A Dose-Finding Study of Sufentanil Sublingual Microtablets for the Management of Postoperative Bunionectomy Pain
Poster #:423
Lead Author: Neil Singla, MD
Presentation date: Thursday, May 1, 2014
Presentation time: 9:30-11:00 ET
Location: Exhibit hall

Title: Sublingual Sufentanil, an "Ideal" Opioid for Acute and Breakthrough Pain: The Clinical Importance $CST_{½}$ and $t_{½ke0}$
Poster #:437
Lead Author: Tong-Joo Gan, MD MHS
Presentation date: Thursday, May 1, 2014
Presentation time: 9:30-11:00 ET
Location: Exhibit hall

Title: Sublingual Sufentanil for Acute Pain Management: Onset of Action
Poster #:418
Lead Author: Harold Minkowitz, MD
Presentation date: Friday, May 2, 2014
Presentation time: 8:45-10:15 ET
Location: Exhibit hall

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso™, is designed to improve the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed patient-controlled analgesia device. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, during the second half of 2014. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Logo - http://photos.prnewswire.com/prnh/20130226/MM67303LOGO

SOURCE AcelRx Pharmaceuticals, Inc.

Timothy E. Morris, Chief Financial Officer, 650.216.3511, tmorris@acelrx.com; Brian Korb, The Trout Group LLC, 646.378.2923, bkorb@troutgroup.com